

10551430

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1612bxr

STNLOGON timed out

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

10551430

NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations

NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in

NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS 22 JUL 28 CA/CAplus patent coverage enhanced

NEWS 23 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register

NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements

NEWS 25 JUL 28 STN Viewer performance improved

NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced

NEWS 27 AUG 13 CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998

NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008

NEWS 29 AUG 15 CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:05:44 ON 20 AUG 2008

FILE 'REGISTRY' ENTERED AT 18:05:50 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3
DICTIONARY FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3

New CAS Information Use Policies, enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

10551430

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\asdfa.str

L1 STRUCTURE UPLOADED

=> s 11
SAMPLE SEARCH INITIATED 18:09:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9617 TO ITERATE

20.8% PROCESSED 2000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTION ANSWERS: 121 TO 647
PROJECTED ITERATIONS: 186462 TO 198218
PROJECTED ANSWERS: 121 TO 647

L2 4 SEA SSS SAM L1

```
=> s 11 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 18:09:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 194565 TO ITERATE
```

100.0% PROCESSED 194565 ITERATIONS 415 ANSWERS
SEARCH TIME: 00.00.01

L3 415 SEA SSS FUL L1

=> file hcaplus		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		181.12	181.33

FILE 'HCAPLUS' ENTERED AT 18:09:50 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 1973).

10551430

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2008 VOL 149 ISS 8
FILE LAST UPDATED: 19 Aug 2008 (20080819/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4          271 L3

=> s 13 and diana, g?/au
      271 L3
      162 DIANA, G?/AU
L5          0 L3 AND DIANA, G?/AU

=> s 14 and bailey, t?/au
      551 BAILEY, T?/AU
L6          0 L4 AND BAILEY, T?/AU

=> s 14 and young, d?/au
      4463 YOUNG, D?/AU
L7          0 L4 AND YOUNG, D?/AU

=> s 14 and chunduru, s?/au
      27 CHUNDURU, S?/AU
L8          0 L4 AND CHUNDURU, S?/AU

=> s 14 and pd < may 2002
      22731637 PD < MAY 2002
      (PD<20020500)
L9          245 L4 AND PD < MAY 2002

=> d 19, ibib abs fhitstr, 1-10

L9  ANSWER 1 OF 245  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:  2002:646274  HCAPLUS
DOCUMENT NUMBER:  137:309665
TITLE:  Stability of biologically active pyridoxal and
        pyridoxal phosphate in the presence of lysine
        Huang, Tzou-Chi; Chen, Ming-Hung; Ho, Chi-Tang
AUTHOR(S):  Huang, Tzou-Chi; Chen, Ming-Hung; Ho, Chi-Tang
CORPORATE SOURCE:  Department of Food Science, National Pingtung
        University of Science and Technology, Pingtung, 912,
        Taiwan
SOURCE:  ACS Symposium Series (2002), 816(Bioactive
        Compounds in Foods), 143-154
```

10551430

CODEN: ACSMC8; ISSN: 0097-6156

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review on the reactivity of pyridoxal and pyridoxal phosphate toward lysine.

IT 13934-04-8


RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(biol. active pyridoxal and pyridoxal phosphate in presence of lysine)

RN 13934-04-8 HCPLUS

CN L-Lysine, N2-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]methylene]-
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:96142 HCPLUS

DOCUMENT NUMBER: 130:172994

TITLE: Polymer based pharmaceutical compositions for targeted delivery of biologically active agents

INVENTOR(S): Lau, John R.; Geho, W. Blair

PATENT ASSIGNEE(S): SDG, Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904824	A1	19990204	WO 1998-US15457	19980724 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2297025	A1	19990204	CA 1998-2297025	19980724 <--
AU 9885912	A	19990216	AU 1998-85912	19980724 <--
EP 999855	A1	20000517	EP 1998-937127	19980724 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE
 JP 2001510811 T 20010807 JP 2000-503875 19980724 <--
 PRIORITY APPLN. INFO.: US 1997-53729P P 19970725
 WO 1998-US15457 W 19980724

AB A polymeric construct for delivering a biol. active agent to a mammal comprises first polymeric matrix, a biol. active agent contained within the polymeric matrix, and a second polymer chemical bound to the biol. active agent. Said second polymer comprising an amino acid copolymer, said second polymer present in an amount effective to reduce leakage of the active agent from the polymeric construct prior to delivery to the desired situs. A solution contained serotonin HCl (I) 0.07, phytic acid 0.18, polylysine 0.18, polylysine-succinyl 0.18, and N-2,6-(diisopropylphenylacrbamoylmethyl)iminodiacetic acid 0.006 mg/mL. When the solution was filtered through a filter with mol. weight cut-off 3000 about 24.2% of I was retained by the filter, presumably due to ionic and/or hydrogen bonding interaction between I and polymeric component of the solution

IT 13934-03-7


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polymer based pharmaceutical compns. for targeted delivery of biol. active agents)

RN 13934-03-7 HCPLUS

CN L-Glutamic acid, N-[(3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl)methylene]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:48605 HCPLUS

DOCUMENT NUMBER: 130:129967

TITLE: Targeted liposomal constructs for diagnostic and therapeutic uses

INVENTOR(S): Geho, Blair W.; Lau, John R.

PATENT ASSIGNEE(S): SDG, Inc., USA

SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9901110	A1	19990114	WO 1998-US13846	19980702 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294900	A1	19990114	CA 1998-2294900	19980702 <--
AU 9882859	A	19990125	AU 1998-82859	19980702 <--
US 6063400	A	20000516	US 1998-109473	19980702 <--
EP 1005327	A1	20000607	EP 1998-933124	19980702 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE				
JP 2000516641	T	20001212	JP 1999-507412	19980702 <--
MX 9911581	A	20000531	MX 1999-11581	19991213 <--
PRIORITY APPLN. INFO.:			US 1997-52740P	P 19970702
			WO 1998-US13846	W 19980702

AB This invention provides a liposomal construct for delivering a diagnostic or therapeutic agent to a mammal comprising a liposomal carrier, a diagnostic or therapeutic agent entrapped within or associated with the liposomal carrier and a sequestering agent distributed within the liposomal carrier to reduce leakage of the diagnostic or therapeutic agent from the liposomal construct prior to delivery. Claimed liposomal constructs include biogenic amines for deliver them to the hepatocytes. ATP was used as a liposomal sequestrant for serotonin along with the lipid membrane constituents of 1,2-distearoyl-sn-glycerol-3-phosphatidylcholine, dicetyl phosphate, N-(2,6-diisopropylphenylcarbamoylmethyl)iminodiacetic acid and cholesterol.

IT 13934-03-7


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeted liposomal constructs containing diagnostic and therapeutic agents and sequestering agents)

RN 13934-03-7 HCPLUS

CN L-Glutamic acid, N-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]methylene]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 4 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:23873 HCPLUS

DOCUMENT NUMBER: 130:182286

TITLE: Domain-Structured N1,N2-Derivatized Hydrazines as

Inhibitors of Ribonucleoside Diphosphate Reductase:
 Redox-Cycling Considerations
 AUTHOR(S): Sarel, Shalom; Fizames, C.; Lavelle, Francois;
 Avramovici-Grisaru, Shelly
 CORPORATE SOURCE: Department of Medicinal Chemistry, Hebrew University
 of Jerusalem, Jerusalem, 91120, Israel
 SOURCE: Journal of Medicinal Chemistry (1999),
 42(2), 242-248
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Eight analogs of 1-[5-halosalicylidene]-2-[2-pyridinoyl]hydrazine and
 -[2-pyridyl]hydrazine, four of 1-[pyridoxylidene]-2-[2-
 pyridinoyl]hydrazine, seven of 1-[pyridoxylidene]-2-[2-pyridyl]hydrazine,
 and one each of 1,2-bis[pyridoxylidene]diaminoethane and
 bis[pyridoxylidenehydrazino]phthalazine were synthesized. Their solns. in
 DMF were assayed for activity against the metalloenzyme ribonucleoside
 diphosphate reductase (RdR), prepared from a s.c. growing murine tumor
 (sarcoma 180) implanted in B6D2F3 male mice. The ¹⁴C-labeled CDP
 reductase was assayed by the modified method of Takeda and Weber, in which
 [¹⁴C]cytidine was separated from deoxycytidine by thin-layer chromatog. on
 cellulose foil. Distribution of radioactivity was assessed with an
 automatic TLC linear analyzer. Of the 31 compds. tested, 13 were
 essentially inactive, 7 were highly active against RdR, and the remaining
 20 were slightly more active than hydroxyurea (used as a reference compound).
 The mechanism of inhibition is discussed in terms of three alternative
 pathways, initiated by sequestration of iron embedded in the R1 subunit of
 the metalloenzyme to form a C-centered chelate radical (via redox
 cycling). Alternatively, the latter could either reduce the tyrosyl
 radical or intercept radicals generated in the reduction process.
 IT 88969-07-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and ribonucleoside diphosphate reductase inhibiting activity of
 pyridinoyl- and pyridylhydrazines)
 RN 88969-07-7 HCPLUS
 CN 3-Pyridinemethanol, 4,4'-(1,2-ethanediylbis(nitrilomethylidyne)]bis[5-
 hydroxy-6-methyl- (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 245 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:458627 HCAPLUS
 DOCUMENT NUMBER: 129:241852
 ORIGINAL REFERENCE NO.: 129:49163a, 49166a
 TITLE: Experimental study on a renal imaging agent
 AUTHOR(S): Zhu, Jun; Ma, Jixiao; Zhu, Ruisen; Xiong, Jiang; Jin, Changqing
 CORPORATE SOURCE: Shanghai 6th People's Hospital, Shanghai, 200233, Peop. Rep. China
 SOURCE: Hejishu (1998), 21(5), 297-300
 CODEN: NUTEDL; ISSN: 0253-3219
 PUBLISHER: Kexue Chubanshe
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

AB The authors report the reactions of glycine, alanine and glycine Et ester with pyridoxal chloride to form the base and the compound chelated with ^{99m}Tc in the presence of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$. In vivo metabolism was also studied. ^{99m}Tc -SB-Gly was rapidly excreted through the kidney into the urine after i.v. injection, with an excretory rate of $79.68 \pm 6.66\text{ID\%}$ in 30min via urine, a little bit lower than ^{99m}Tc -DTPA ($82.56 \pm 6.88\text{ID\%}$), but having a clear renal scintigraphy. Elimination in blood was rapid. In inhibition expts. with probenecid in rats, the urine excretion rate was not affected, suggesting that this compound passed through by glomerular filtration.


IT 70837-00-2DP, ^{99m}Tc complexes
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (biodistribution of renal imaging agents: ^{99m}Tc complexes with pyridoxal-amino acid derivs.)

RN 70837-00-2 HCAPLUS

10551430

CN Pyridinium, 4-[[[(1S)-1-carboxyethyl]imino]methyl]-3-hydroxy-5-(hydroxymethyl)-1,2-dimethyl-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



● Cl⁻

L9 ANSWER 6 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:175940 HCPLUS
DOCUMENT NUMBER: 128:241251
ORIGINAL REFERENCE NO.: 128:47697a, 47700a
TITLE: Human salivary proteins CON-1 and CON-2 having alpha-glucosidase-inhibiting activity and their use in treatment of HIV-1 infection and diabetes
INVENTOR(S): Azen, Edwin A.; Pan, David
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809981	A1	19980312	WO 1997-US15799	19970908 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9743359	A	19980326	AU 1997-43359	19970908 <--
US 5981720	A	19991109	US 1997-925237	19970908 <--
PRIORITY APPLN. INFO.:			US 1996-24712P	P 19960909
			WO 1997-US15799	W 19970908

AB Human salivary proteins CON-1 and CON-2 and fragments thereof having alpha-glucosidase inhibitory activity and methods of using same for the

treatment of diabetes and AIDS are disclosed. CON-1 and CON-2 were purified from human saliva. They were found to be glycoproteins. CON-1 inhibited α -glucosidase but removal of carbohydrates from CON-1 decreased its inhibitory activity by 50%. CON-1 reduced HIV-1 proliferation in CEMx174 cells infected with the retrovirus. Protease digestion of CON-1 produced a glycotetrapeptide Gly-Gly-Asn(N-acetyl- β -D-glucosamine)-Lys which also displayed α -glucosidase-inhibiting activity.

IT 204757-17-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human salivary proteins CON-1 and CON-2 having alpha-glucosidase-inhibiting activity and their use in treatment of HIV-1 infection and diabetes)

RN 204757-17-5 HCPLUS

CN L-Lysine, glycylglycyl-N-[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-L-asparaginyl-N6-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:126640 HCPLUS

DOCUMENT NUMBER: 128:235002

ORIGINAL REFERENCE NO.: 128:46417a, 46420a

TITLE: Skin preparations containing amino acids, antioxidants, and metal-chelating agents

INVENTOR(S): Iwasaki, Keiji; Kitazawa, Manabu

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

10551430

JP 10053515 A 19980224 JP 1996-211229 19960809 <--
PRIORITY APPLN. INFO.: MARPAT 128:235002 JP 1996-211229 19960809

OTHER SOURCE(S): MARPAT 128:235002

AB Skin preps., which are safe and show long-lasting active O-inhibiting activity, contain ArXCHR(CH₂)_nY [Ar = (substituted) 2-hydroxyphenyl, 2-hydroxy-1-naphthyl, pyridyl; R = amino acid side chain; X = CH₂NH, CH:N; Y = H, CO₂R₁, SO₃H, CONR₂R₃, CONHCHR₅CO₂R₄; CH₂OH; R₁-R₄ = H, C₁-6 alkyl; R₅ = amino acid side chain; n = 0, 1] or their salts, antioxidants, and metal-chelating agents. N-(4-pyridoxylmethylene)-L-serine (I), preparation given) 0.1, α -tocopherol 0.5, Na ascorbate 0.5, cetanol 5.0, polyoxyethylene cetyl ether 2.0, olive oil 2.0, propylene glycol 3.0, and H₂O to 100 weight% were mixed to give a skin preparation, which was stored at 40° under light irradiation for 3 mo to show 97% I stability.

IT 13933-86-3P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(active O-inhibiting skin preps. containing amino acids, antioxidants, and metal-chelating agents)

RN 13933-86-3 HCPLUS

CN L-Serine, N-[(3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl)methylene]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L9 ANSWER 8 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:126458 HCPLUS

DOCUMENT NUMBER: 128:205039

ORIGINAL REFERENCE NO.: 128:40559a, 40562a

TITLE: Preparation and biological activity of antimicrobial steroidal amino compounds

INVENTOR(S): Schoenecker, Bruno; Wyrwa, Ralf; Moellmann, Ute; Krieg, Reimar; Dubs, Manuela

PATENT ASSIGNEE(S): Friedrich-Schiller-Universitaet Jena, Germany; Hans-Knoell-Institut fuer Naturstoffforschung

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.


DATE

 DE 19633206 A1 19980219 DE 1996-19633206 19960817 <--
 DE 19633206 C2 20010329
 PRIORITY APPLN. INFO.: DE 1996-19633206 19960817
 OTHER SOURCE(S): MARPAT 128:205039
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Steroidal amines [RNR1R5aCR2R3R4]a+ Aa- [a = 0, 1; R = steroid, cholanyl, cardenolide, bufadienolide derivative; R1 - R5 = H, alkyl; A = anion; when a = 0: R1R2 = bond; R3 = (CH₂)_xR₆, x ≥ 0; R₆ = (un)substituted Ph, pyridyl, pyrrolyl, furyl, thiienyl, ferrocenyl; R4 = H, alkyl, R₃; or when a = 0: R1 = H, alkyl, aryl, acyl, (CH₂)_yR₃, y ≥ 0; R2 = H; R3 = (CH₂)_xR₆; R4 = H, alkyl, R₃; when a = 1: R1 = H, alkyl, aryl; R2 = H; R3 = (CH₂)_xR₆; R4 = H, alkyl, R₃; R5 = H, alkyl, (CH₂)_yR₇; R7 = (un)substituted Ph, pyridyl, pyrrolyl, furyl, thiienyl, ferrocenyl], [I]a+ Aa- (R₈, R₉ = H, halo, NO₂, OH, alkoxy, aryloxy, acyloxy, acyl, alkyl, aryl; R₁₀ = NR₁R₅aCR₂R₃R₄), [II]a+ Aa- , [III]a+ Aa- and [IV]a+ Aa- with antimicrobial activity were prepared from the resp. aminosteroids. Steroid I [R1 = R₂ = R₄ = H, R₃ = 2-pyridylmethyl, R₈ = β-OH, R₉ = OMe, a = 0 (V)] was prepared via reaction of 16β-amino-3-methoxyestra-1,3,5(10)-trien-17β-ol with α-vinylpyridine in MeOH followed by treatment with AcOH. V showed antibacterial activity [25 μg/mL vs. Mycobact. smeg. (SG 987) and Mycobact. fort. B; 12.5 μg/mL vs. Mycobact. chel. B and Mycobact. aurum (SB 66); 12.5 μg/mL vs. Mycobact. vaccae (10670)].
 IT 203725-62-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antimicrobial activity of steroidal amines)
 RN 203725-62-6 HCPLUS
 CN Estra-1,3,5(10)-trien-17-ol, 16-[[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]methylene]amino]-3-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



L9 ANSWER 9 OF 245 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:294750 HCAPLUS
 DOCUMENT NUMBER: 127:41278
 ORIGINAL REFERENCE NO.: 127:7783a,7786a
 TITLE: Complexes of Mn(II) and Mn(III) with the Schiff base
 N-[2-(3-ethylindole)]pyridoxaldimine. Electrochemical
 study of these and related Ni(II) and Cu(II) complexes
 Gili, P.; Reyes, M. G. Martin; Zarza, P. Martin;
 Guedesda Silva, M. F. C.; Tong, Y.-Y.; Pombeiro, A. J. J.
 L.
 CORPORATE SOURCE: Dep. Quimica Inorganica, Fac. Farmacia, Univ. La
 Laguna, Tenerife, Canary Islands, Spain
 SOURCE: Inorganica Chimica Acta (1997), 255(2),
 279-288
 CODEN: ICHAA3; ISSN: 0020-1693
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB New complexes of Mn(II) and Mn(III) with the monoanionic bidentate ligand
 N-[2-(3-ethylindole)]pyridoxaldimine (pyrdoxTPA) are described. They were
 characterized by IR and electronic spectroscopies, magnetic measurements
 and thermogravimetric and calorimetric studies. The spectroscopic and
 magnetic data indicate a tetrahedral coordination for the Mn(II) complex
 and a five-coordination for the Mn(III) complex. An electrochem. study of
 the Mn(II) and analogous Ni(II) and Cu(II) complexes with the same ligand
 is reported. As indicated by cyclic voltammetry and controlled potential
 electrolysis, in aprotic medium, the complexes display redox processes
 involving either the M(II)/M(III) (M = Mn, Ni or Cu) or the M(II)/M(I) (M
 = Ni or Cu) metal redox pairs, and the pyrdoxTPA ligands. The values of
 the redox potential of the metal centered redox processes follow the order
 of those of the corresponding ionization potential of the gaseous metal
 ions, and for the Mn(II) and Ni(II) complexes evidence is presented for the
 occurrence of anodically induced trimerizations.
 IT 98497-88-2
 RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
 (reaction with manganese acetate and elec. potential in DMSO)
 RN 98497-88-2 HCAPLUS
 CN 3-Pyridinemethanol, 5-hydroxy-4-[[[2-(1H-indol-3-yl)ethyl]imino]methyl]-6-
 methyl- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMATORY.

L9 ANSWER 10 OF 245 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:244284 HCPLUS
DOCUMENT NUMBER: 126:232709

ORIGINAL REFERENCE NO.: 126:44851a, 44854a
 TITLE: Preparation of magnesium pyridoxal-5'-phosphateglutamate and its intermediate.
 INVENTOR(S): Maidonis, Panagiotis; Schneider, Werner
 PATENT ASSIGNEE(S): Steigerwald Arzneimittelwerk GmbH, Germany
 SOURCE: Ger. Offen., 8 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19532625	A1	19970306	DE 1995-19532625	19950904 <--
DE 19532625	C2	20000420		
CA 2230555	A1	19970313	CA 1996-2230555	19960826 <--
WO 9709334	A1	19970313	WO 1996-EP3749	19960826 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
AU 9669845	A	19970327	AU 1996-69845	19960826 <--
AU 706162	B2	19990610		
EP 861258	A1	19980902	EP 1996-930965	19960826 <--
EP 861258	B1	20011121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1199402	A	19981118	CN 1996-197528	19960826 <--
HU 9802778	A2	19990928	HU 1998-2778	19960826 <--
HU 9802778	A3	20010228		
JP 11512103	T	19991019	JP 1996-510820	19960826 <--
AT 209210	T	20011215	AT 1996-930965	19960826 <--
ES 2165521	T3	20020316	ES 1996-930965	19960826 <--
PT 861258	T	20020531	PT 1996-930965	19960826
CZ 292662	B6	20031112	CZ 1998-591	19960826
IN 1996CA01512	A	20050304	IN 1996-CA1512	19960826
EG 20974	A	20000830	EG 1996-794	19960831 <--
TW 442472	B	20010623	TW 1996-85110753	19960903 <--
HR 960401	B1	20011031	HR 1996-401	19960903 <--
US 5962687	A	19991005	US 1998-29426	19980629 <--
HK 1014958	A1	20020328	HK 1999-100006	19990104 <--
PRIORITY APPLN. INFO.:			DE 1995-19532625	A 19950904
			WO 1996-EP3749	W 19960826

AB Mg5L2 (L5- = pyridoxal-5'-phosphateglutamate) was prepared by the reaction of Mg glutamate and pyridoxal-5'-phosphate. Pyridoxal-5'-phosphate was prepared by a stepwise method starting from pyridoxin hydrochloride oxidation by MnO₂ giving pyridoxal which was reacted with p-phenetidine. P-phenetidylpyridoxal was prepared by this latter reaction and reacted with polyphosphoric acid to give p-phenetidylpyridoxal-5'-phosphate which was deprotected to give pyridoxal-5'-phosphate.

IT 4943-90-2P
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

10551430

(for preparation of magnesium pyridoxal-5'-phosphateglutamate)
RN 4943-90-2 HCAPLUS
CN 3-Pyridinemethanol, 4-[[[(4-ethoxyphenyl)imino]methyl]-5-hydroxy-6-methyl-
(CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 18:05:44 ON 20 AUG 2008)

FILE 'REGISTRY' ENTERED AT 18:05:50 ON 20 AUG 2008

L1 STRUCTURE uploaded
L2 4 S L1
L3 415 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 18:09:50 ON 20 AUG 2008

L4 271 S L3
L5 0 S L3 AND DIANA, G?/AU
L6 0 S L4 AND BAILEY, T?/AU
L7 0 S L4 AND YOUNG, D?/AU
L8 0 S L4 AND CHUNDURU, S?/AU
L9 245 S L4 AND PD < MAY 2002

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	135.20	316.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

FILE 'CAOLD' ENTERED AT 18:27:51 ON 20 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

10551430

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13
L10 16 L3

=> d 110, all, 1-16

L10 ANSWER 1 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA65:18644e CAOLD
TI conversion of 10 β , 17 β -dehydroxyestra-1,4-dien-3-one to 3-aminoestra-1,3,5(10)-trien-17 β -ol
AU Schmialek, Peter; Danneberg, H.
IT 549-02-0 10427-24-4 13144-83-7

L10 ANSWER 2 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA65:12665f CAOLD
TI formation of pyridoxal phosphate Schiff's base-inherent defect in the tryptophan load test
AU Hughes, P. A. M.; Raine, D. N.
IT 59-00-7 13311-34-7 13311-40-5

L10 ANSWER 3 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA64:8154c CAOLD
TI pyridine derivs. (S-containing)
PA Merck, E., A.-G.
DT Patent
PATENT NO. KIND DATE
----- -----
PI NL 6412891
BE 655454
GB 1032377
IT 4632-27-3 4943-89-9 4943-90-2
4943-91-3 4943-92-4 4943-93-5 4943-94-6 4943-95-7 4944-01-8
4943-96-8 4943-97-9 4943-98-0 4943-99-1 4944-00-7 4944-01-8
4944-02-9 4944-03-0 4944-04-1 4959-62-0 4959-63-1 4959-64-2
4959-65-3 4959-66-4 4959-67-5 4999-97-7 4999-98-8 4999-99-9
5000-00-0 5000-01-1 5000-02-2 5000-03-3 5000-04-4 5000-05-5
5000-06-6 5000-07-7 5000-08-8 5000-09-9 5000-10-2 5000-11-3
5000-12-4 5000-13-5 5000-14-6 5004-89-7 5004-90-0 5009-62-1
5196-15-6 5196-16-7 5196-17-8 5196-18-9 5365-50-4 5365-58-2
5365-59-3 5365-60-6 5365-61-7 5365-62-8 5365-63-9 5365-64-0
5365-65-1 5365-66-2 5508-97-4 5508-98-5 5572-76-9 5575-18-8

10551430

5589-33-3 5589-34-4 30587-24-7 30587-25-8 30587-26-9 30644-49-6
91252-36-7 106504-00-1

L10 ANSWER 4 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA64:8154b CAOLD
TI pyridoxal Schiff bases
AU Murakami, Masuo; Iwanami, M.; Kawai, R.
PA Yamanouchi Pharmaceutical Co., Ltd.
DT Patent
PATENT NO. KIND DATE
----- -----
PI JP 65026820 1965
IT 4943-87-7 4943-88-8 5004-88-6

L10 ANSWER 5 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA63:19f CAOLD
TI reaction of pyridoxal phosphate with amines and its anal. application
AU Gaudiano, Aldo; Polizzi-Sciarrone, M.
IT 54-47-7 66-72-8 1499-44-1 1499-45-2

L10 ANSWER 6 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA62:12048b CAOLD
TI anomalous rotatory dispersion of metal chelates of aldimines of
α-amino acids and their derivs.-determination of absolute configuration
AU Torchinskii, Yu. M.; Koreneva, L. G.
IT 2949-29-3 3269-00-9 3269-01-0 3269-02-1 3444-19-7
3444-20-0 3444-21-1 3444-22-2 3444-23-3 3444-24-4 3444-25-5
3444-26-6 3444-27-7 3444-28-8 3444-29-9 3487-08-9
3520-81-8 3577-08-0 3908-17-6 4055-44-1

L10 ANSWER 7 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA57:15481a CAOLD
TI erythropoietin
AU De Ritis, Giancarlo
TI semicarbazone formation from pyridoxal, pyridoxal phosphate, and their
Schiff bases
AU Cordes, Eugene H.; Jencks, W. P.
IT 781-66-8 1499-44-1 76532-72-4 91761-12-5
93353-85-6 93606-21-4 93688-51-8 96218-00-7

L10 ANSWER 8 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA56:9354c CAOLD
TI effects of various hormones on the activity and systemic content of
histaminase
AU Negishi, Tadamichi
IT 125-04-2 302-25-0 979-32-8 6151-12-8 13331-81-2
13331-82-3 17433-39-5 73622-67-0 73713-65-2 73758-58-4
73840-48-9 73840-49-0 73840-50-3 74037-54-0 82276-93-5
91982-30-8 93884-10-7

L10 ANSWER 9 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA56:1698c CAOLD
TI chelation therapy in circulatory and sclerosing diseases
AU Boyle, Albert J.; Clarke, N. E.; Mosher, R. E.; McCann, D. S.
TI metal-binding by pyridoxal derivs. and possible relations to tryptophan
metabolism

10551430

AU Metzler, David E.
TI trace minerals, chelating agents, and the porphyrias
AU Peters, Henry A.
IT 1499-45-2 13933-92-1 13933-97-6
13934-03-7 57212-58-5 63221-70-5
91200-59-8 93353-85-6

L10 ANSWER 10 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA53:7165b CAOLD
TI furoyl and furfuyl derivs. of pyridoxamine
AU McCasland, G. E.; Blanz, E., Jr.; Furst, A.
IT 4664-26-0 102313-26-8 103649-84-9 109401-44-7 114133-79-8
114493-09-3

L10 ANSWER 11 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA52:2960g CAOLD
TI protective effect of N-pyridoxylidene-L-cysteine against x-ray irradiation
AU Yamada, Kozo; Hayami, S.; Sawaki, S.
IT 13933-88-5

L10 ANSWER 12 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA51:18006i CAOLD
TI 4-pyridoxylamino-3-isoxazolidinones
PA Merck & Co., Inc.
DT Patent
TI 4-pyridoxylamino-3-isoxazolidinones
AU Folkers, Karl
DT Patent
PATENT NO. KIND DATE
----- -----
PI US 2801248 1957
IT 101495-73-2 101568-92-7 101655-14-5
106273-77-2

L10 ANSWER 13 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA51:8804h CAOLD
TI 4-pyridoxylamino-3-isoxazolidinones
PA Merck & Co., Inc.
DT Patent
TI 4-pyridoxylamino-3-isoxazolidinones
AU Folkers, Karl
DT Patent
PATENT NO. KIND DATE
----- -----
PI US 2776296 1957
IT 101495-73-2 101568-92-7 101655-14-5 102015-45-2
106273-77-2

L10 ANSWER 14 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA51:5870i CAOLD
TI equilibrium between pyridoxal and amino acids and their imines
AU Metzler, David E.
IT 1499-45-2 6956-94-1 7146-98-7
13933-86-3 13933-92-1 13933-97-6
13934-01-5 13934-03-7 17390-01-1
19973-35-4 57212-58-5 57237-43-1

10551430

63221-70-5 74317-99-0 91200-59-8
91761-12-5 93353-85-6 93688-50-7
100377-38-6 102015-20-3

L10 ANSWER 15 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA51:587i CAOLD
TI biochem. aspects of atherosclerosis
AU Anfinsen, Christian B.
IT 57211-84-4

L10 ANSWER 16 OF 16 CAOLD COPYRIGHT 2008 ACS on STN
AN CA51:587b CAOLD
TI acute nephrosis following bleeding caused by lack of fibrin
AU Runge, Hans; Pfau, P.
IT 57211-84-4

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.50	328.03
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'REGISTRY' ENTERED AT 18:28:07 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3
DICTIONARY FILE UPDATES: 19 AUG 2008 HIGHEST RN 1042061-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> S 57211-84-4/RN

L11 1 57211-84-4/RN

Updated Search

10551430

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L11 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 57211-84-4 REGISTRY

CN 3-Pyridinemethanol, 5-hydroxy-6-methyl-4-[(1-methylpropyl)imino]methyl-
(CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 3-Pyridinemethanol, 4-(N-sec-butylformimidoyl)-5-hydroxy-6-methyl- (6CI)
MF C12 H18 N2 O2

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: PREP (Preparation); PRP (Properties); RACT
(Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED